Japanese Journal of Clinical Oncology 33:371-376 (2003)
© 2003 Foundation for Promotion of Cancer Research
Multicenter Phase II Trial of Weekly Paclitaxel for Advanced or Metastatic Breast Cancer: the Saitama Breast Cancer Clinical Study Group (SBCCSG-01)
1 Department of Surgery I, National Defense Medical College, Tokorozawa, Saitama, 2 Division of Breast Oncology, Saitama Cancer Center, Kitaadachi-gun, Saitama, 3 Saitama Red Cross Hospital, Saitama, 4 Jichi Medical School, Omiya Medical Center, Saitama, 5 Kawaguchi Medical Center, Kawaguchi, Saitama, 6 Saitama Medical School, Iruma-gun, Saitama and 7 Saitama Social Insurance Hospital, Saitama, Japan
Objective: Weekly dosing of paclitaxel has been demonstrated to be a well-tolerated, feasible and effective administration schedule. In this study, we evaluated the efficacy and safety of weekly paclitaxel in Japanese women with advanced or metastatic breast cancer.
Methods: Seventy-four patients were enrolled in the study. Paclitaxel was administered by 1 h intravenous infusion at a dose of 80 mg/m2 every week. Administration was continued for 3 weeks followed by a 1 week rest. A short premedication, consisting of dexamethasone 10 mg, ranitidine 50 mg and diphenylhydramine 50 mg, was given prior to each dose of paclitaxel. Eligibility criteria included an Eastern Cooperative Oncology Group performance status of 0, 1 or 2 and adequate hematological, hepatic and renal function.
Results: Of 74 patients treated and evaluable for toxicities, 70 were evaluable for response. The mean age was 57.7 years. Forty-nine patients (66.2%) had received prior anthracyclines for metastatic diseases. The overall response rate among 74 patients was 40.5%, including 4.1% complete responses and 36.5% partial responses. The median follow-up time was 481 days (range, 24–903 days). The median time to progression was 4.8 months and median overall survival was 15.8 months. The majority of patients tolerated the treatment very well. Although alopecia was observed in most of the patients (93.2%), grade 3 or 4 neutropenia was 10.8% and grade 2 or 3 peripheral neuropathy was 13.5%.
Conclusion: Weekly paclitaxel as a 1 h infusion was active and generally well tolerated in previously treated patients. Further study of weekly paclitaxel in combination therapy is warranted.
+ For reprints and all correspondence: Kazuhiko Sato, Department of Surgery I, National Defense Medical College, 3–2 Namiki, Tokorozawa, Saitama 359-8513, Japan. E-mail: sato-k-a{at}mtg.biglobe.ne.jp
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  T. ISHIKAWA, S. SHIMIZU, K. KATAYAMA, T. CHISHIMA, Y. HAMAGUCHI, T. DOI, M. TANABE, A. KASAHARA, N. YAMAGUCHI, K. NARUI, et al. Feasibility of AC/EC Followed by Weekly Paclitaxel in Node-positive Breast Cancer in Japan Anticancer Res, May 1, 2009; 29(5): 1515 - 1520. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. HORIGUCHI, Y. RAI, K. TAMURA, T. TAKI, K. HISAMATSU, Y. ITO, T. SERIU, and T. TAJIMA Phase II Study of Weekly Paclitaxel for Advanced or Metastatic Breast Cancer in Japan Anticancer Res, February 1, 2009; 29(2): 625 - 630. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Gonzalez-Angulo and G. N. Hortobagyi Optimal Schedule of Paclitaxel: Weekly Is Better J. Clin. Oncol., April 1, 2008; 26(10): 1585 - 1587. [Full Text] [PDF]
|
|
|
|
|
|
A. D. Seidman, D. Berry, C. Cirrincione, L. Harris, H. Muss, P. K. Marcom, G. Gipson, H. Burstein, D. Lake, C. L. Shapiro, et al. Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer and Leukemia Group B Protocol 9840 J. Clin. Oncol., April 1, 2008; 26(10): 1642 - 1649. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Eniu, F. M. Palmieri, and E. A. Perez Weekly Administration of Docetaxel and Paclitaxel in Metastatic or Advanced Breast Cancer Oncologist, October 1, 2005; 10(9): 665 - 685. [Abstract] [Full Text] [PDF]
|
|